It has been shown that such tumors can be better treated with transtuzumab in combination with PI3K/AKT inhibitor which is also effective against cancer stem cells (CSC), a population hypothesized to be responsible for therapy resistance and cancer reoccurrence [38]. This evidence concerns the gene PIK3CA and cancer.